News & Articles

Thermo Fisher Scientific's forum focuses on strategies to expedite biotherapeutic development and commercialization

The diagnostic assay can be used to help diagnose patients with non-small cell lung cancer

New collaboration to focus on developing potent Affimer-drug conjugates

Combining urine strip reading and digital microscopy, the LAURA XL delivers fully automated processing of urine samples

Designed specifically for smaller biobanks the BB package simplifies sample integrity, tracking and audit trail.

Corning Elplasia plates and Matrigel matrix for organoid culture are designed to help develop more predictive models for cancer and other critical diseases

Automated system designed to increase efficiency in cell therapy research

SelectScience is heading to Chicago, USA, to interview scientists at the forefront of neuroscience research and report on the latest techniques and technologies advancing the field

Discover how one lab is using patient-derived pancreatic organoids to deliver personalized treatments

Join this expert webinar to find out all you need to know about an innovative new method for tackling the first step of mAb purification

Roche's assay to be used to find patients eligible for treatment with Tecentriq in combination with Abraxane

First collaboration product includes medical imaging capabilities to enable more personalized treatment decisions in cancer care

The VENTANA ROS1 (SP384) rabbit monoclonal primary antibody is designed to effectively identify elevated ROS1 protein expression

We celebrate the clinical laboratory products that have made the most difference to your lab work or point-of-care testing and reveal our most popular clinical content of the year

3D InSight Human Liver Disease platform provides the most physiologically relevant testing environment for efficacy and safety

Drop by and see SelectScience on booth #724 at this year's AACC conference in Anaheim, California, from August 4-8

Explore the techniques and technologies that are shaping the latest advancements in cancer research

Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies

Help us celebrate the best new clinical assays, kits, instruments and devices by casting your vote today

IMMray™ PanCan-d blood-based test for early detection of pancreatic cancer now set for Q3 2020 launch